Botox Maker Settles Charges for $600 Million
Allergan, the makers of Botox, have agreed to pay a $600 million settlement for charges that the company promoted the off-label use of the drug. According to the complaint, Allergan had a marketing program in place that would include “kickbacks” to doctors for prescribing Botox for things that it hasn’t been approved for, like pain treatment. The FDA is considering approval for Botox’s use in treating chronic migraines.
Allergan spokeswoman Caroline Van Hove denied kickback and fraud allegations in an emailed statement to the New York Times.
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in